Enlivex Ltd. (ENLV) Form 6-K — Jul 13, 2026
The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to Allocetra for the treatment of age-related symptomatic knee osteoarthritis in patients aged 64 and older. This designation is based on clinical evidence from a completed Phase I/IIa trial where treated patients experienced statistically significant improvements in knee pain and physical function compared with placebo.
Key figures
- Topline data date
- 2027-Q2
- Oa prevalence 2040
- 78 million
- Phase2b enrollment
- 182
- Oa prevalence current
- 32 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.